AstraZeneca
AstraZeneca’s thyroid cancer drug gets CHMP nod
November 21, 2011Sales and Marketing AstraZeneca, CHMP, Caprelsa, vandetanib
AstraZeneca’s thyroid cancer pill Caprelsa has taken a step closer to European approval after being recommended by the CHMP.Caprelsa (vandetanib) …
AstraZeneca’s UK research centre prepares to close
November 18, 2011Research and Development AstraZeneca, Charnwood
AstraZeneca has thrown more light on the pending closure of its UK R&D site in Charnwood, saying that 90% of …
NICE won’t back Faslodex in breast cancer
November 10, 2011Sales and Marketing AstraZeneca, Faslodex, NICE
NICE has not recommended AstraZeneca’s breast cancer drug Faslodex as it says the drug is no better than existing treatments. …
AZ and Targacept’s novel depression drug misses target
November 8, 2011Research and Development, Sales and Marketing AstraZeneca
AstraZeneca and Targacept’s next generation depression drug has failed to meet its primary endpoint in a late-stage trial. The first …
AstraZeneca weathers patent expiry storm
October 27, 2011Sales and Marketing AstraZeneca, AstraZenecca, q3 2011
AstraZeneca saw its revenue decline in the third quarter due to an onslaught of patent expiries, but still saw its …
AstraZeneca plans $200m manufacturing plant in China
October 11, 2011Manufacturing and Production AstraZeneca, China, pharma manufacturing news
AstraZeneca has announced plans to set up a manufacturing facility in north-eastern China, backed by a record investment by the …
Trial disappointment for AZ lung cancer drug
October 3, 2011Research and Development, Sales and Marketing AstraZeneca, selumetinib
AstraZeneca’s lung cancer drug selumetinib has failed to hit its primary endpoint in a Phase II trial. The trial compared …
AZ details US doctor payments
August 24, 2011Sales and Marketing AstraZeneca, industry reputation, payments
AstraZeneca is shining a light on its activities in the US, disclosing for the first time how much it pays …
NICE blames Faslodex rejection on uncertainties in AZ data
August 23, 2011Sales and Marketing AstraZeneca, Faslodex, NICE, breast cancer
NICE has not recommended a high-dose form of AstraZeneca’s breast cancer drug Faslodex because of uncertainties over its cost-effectiveness. In …
FDA approves AstraZeneca’s Brilinta after delay
July 21, 2011Sales and Marketing AstraZeneca, Brilinta, Brilique, antiplatelet
The FDA has finally approved AstraZeneca’s oral blood thinner Brilinta after asking for more information on the drug last year. …
Future of AZ-BMS diabetes drug in doubt
July 20, 2011Research and Development, Sales and Marketing AstraZeneca, BMS, dapagliflozin, diabetes, research and development news
A US advisory committee has rejected an investigational compound for type II diabetes sufferers, throwing its future into doubt. Dapagliflozin, …
AstraZeneca signs cancer drug discovery collaboration
June 30, 2011Research and Development AstraZeneca, PTC Therapeutics
AstraZeneca has signed a deal with PTC Therapeutics to use the company’s proprietary drug discovery platform to discover new cancer …
AstraZeneca sells off dental business for $1.8bn
June 23, 2011Sales and Marketing AstraZeneca, strategy
AstraZeneca is to sell its dental products firm Astra Tech to DENTSPLY for $1.8 billion. Astra Tech comprises two business …
AZ establishes predictive science centre in Russia
June 17, 2011Research and Development AstraZeneca, Russia, predictive science
AstraZeneca is moving further into Russia with the establishment in St. Petersburg of a facility which aims to better assess …
AstraZeneca to stop paying for international conference trips
June 2, 2011Medical Communications, Sales and Marketing AstraZeneca, congresses, ethics
AstraZeneca will no longer pay for doctors to attend international conferences. The move is the latest development in the industry’s …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
